We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

By LabMedica International staff writers
Posted on 17 May 2023
Print article
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints in laboratory workflows and staffing can lead to delays in providing test results to physicians and patients. A new pair of hematology analyzers now addresses these issues by offering user-friendly interfaces and the ability to connect multiple analyzers, effectively eliminating workflow bottlenecks and delivering the fast processing times needed in high-volume labs. These analyzers also offer integrated rules-based testing, which allows lab technicians of varying experience levels to interpret complex patient results and respond promptly.

Siemens Healthineers (Erlangen, Germany) has introduced two novel solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. The complete blood count (CBC), a vital component of patient care, is one of the most frequently conducted diagnostic tests in the lab and often provides the first sign of a patient's illness. Physicians rely heavily on labs to deliver crucial hematology data reliably. Traditionally, hematology testing is a complex, time-sensitive process that necessitates skilled laboratory personnel to evaluate results before they can be relayed to physicians. The widespread use of CBC testing and escalating staff shortages can impact a lab's capacity to quickly review and release patients' test results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers offer integrated automation and intelligence designed to overcome these challenges, thereby enhancing workflow efficiency and speeding up patient results delivery.

In hospital or critical care settings, the expected turnaround time for routine CBCs is typically less than an hour, while for STATs, it is ideally less than 10 minutes. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers can generate a throughput of up to 120 tests per hour. Their intuitive designs significantly decrease time-intensive daily maintenance while enabling quick reagent changes. Patients in critical condition, such as those with cancer, renal conditions, or neonates, require hematology testing to monitor their progress and guide adjustments to their care. Small changes in patient results can have significant implications if they are not flagged or if they are misinterpreted. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers incorporate advanced data management capabilities to address the expertise gap in labs, thus enabling staff of all skill levels to interpret results accurately.

The analyzers' rules-based auto-validation feature can release normal results—those that do not violate predefined criteria—directly into a laboratory information system, thereby saving time and enabling physicians to receive information more quickly. Any abnormalities are flagged and categorized by severity to clearly signify which patient samples need more detailed examination by a technician. When results necessitate further steps such as dilutions or slide reviews, standardized instructions can be displayed to ensure staff follows lab protocols. The Atellica HEMA 570 Analyzer measures 43 cell parameters, while the Atellica HEMA 580 Analyzer offers an additional 12 parameters, including indicators of immature red blood cells relevant to certain patient populations and an optical-based platelet count that reduces analytical interferences common in other detection technologies. Up to six Atellica HEMA 570 and Atellica HEMA 580 Analyzers can be integrated together to maximize throughput with intelligent, automated workload balancing and reflexive testing that minimizes operator involvement.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Complement 3 (C3) Test
GPP-100 C3 Kit
Chikungunya & Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.